Presented at ALA meeting at COSM, May 1st, 2008, Orlando, FL (resident research award).
Laryngeal Transplantation in the Setting of Cancer: A Rat Model†
Article first published online: 2 JAN 2009
Copyright © 2008 The Triological Society
Volume 118, Issue 12, pages 2166–2171, December 2008
How to Cite
Shipchandler, T. Z., Lorenz, R. R., Lee, W. T., Teker, A. M., Dan, O. and Strome, M. (2008), Laryngeal Transplantation in the Setting of Cancer: A Rat Model. The Laryngoscope, 118: 2166–2171. doi: 10.1097/MLG.0b013e3181855108
Supported by a Research Programs Committee Internal grant from Cleveland Clinic.
- Issue published online: 2 JAN 2009
- Article first published online: 2 JAN 2009
- Manuscript Accepted: 1 JUL 2008
- Laryngeal transplantation;
- squamous cell carcinoma;
- tumor cell line
Objective: Traditional immunosuppressive regimens make laryngeal transplantation in cancer patients prohibitive because of the increased risk of recurrence. Everolimus, a recently developed immunosuppressant, has demonstrated significant antitumor properties. The purpose of this study was to examine the effects of everolimus alone and in combination with other immunosuppressants on tumor growth in a combined laryngeal transplantation and tumor model.
Study Design: Animal, prospective, randomized, controlled, and blinded.
Methods: One million squamous cell carcinoma cells (SCC-158) were injected intravenously into a total of 40 rats 1 day before laryngeal transplantation. Rats were divided into four groups differing by immunosuppressive regimens. Lung surface metastases were counted 21 days after inoculation, and numerical transplantation rejection scores were recorded. A separate experiment for comparison was performed with no transplant on 24 rats, but with the same immunosuppressive treatment groups.
Results: The median number of lung surface metastases were: a) control (i.e., no immunosuppression): 85; b) everolimus 1.0 mg/kg: 25; c) tacrolimus 1.2 mg/kg: 1650; d) everolimus 1.0 mg/kg + tacrolimus 0.05 mg/kg: 1300. Rats receiving everolimus alone showed a statistically significant decrease in pulmonary surface metastases compared with the other groups. Transplanted rats had no difference in their outcomes when compared with nontransplanted rats.
Conclusion: Everolimus significantly decreases SCC-158 growth in our combined transplantation and tumor model compared with controls and other immunosuppressants.